Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis : a matched cohort study. / Thyssen, Jacob P; Nymand, Lea K; Maul, Julia-Tatjana; Schmid-Grendelmeier, Peter; Wu, Jashin J; Thomsen, Simon Francis; Egeberg, Alexander.
I: Journal of the European Academy of Dermatology and Venereology : JEADV, Bind 36, Nr. 6, 2022, s. 890-896.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis
T2 - a matched cohort study
AU - Thyssen, Jacob P
AU - Nymand, Lea K
AU - Maul, Julia-Tatjana
AU - Schmid-Grendelmeier, Peter
AU - Wu, Jashin J
AU - Thomsen, Simon Francis
AU - Egeberg, Alexander
N1 - © 2022 European Academy of Dermatology and Venereology.
PY - 2022
Y1 - 2022
N2 - BACKGROUND: Use of Janus kinase 1 inhibitors in moderate-to-severe atopic dermatitis (AD) is associated with incident acne in adolescent and adults that is mostly mild, transient and treatable. There is a need for more knowledge about the risk and severity of acne in patients with AD.OBJECTIVES: To examine the prevalence, incidence and risk of acne in adolescents and adults with AD using nationwide prescription data.METHODS: A matched cohort study of 6600 adults with AD and 66 000 controls was conducted using routinely and prospectively collected nationwide administrative data. Adjusted hazard ratios (HR) are reported with 95% confidence intervals (CIs).RESULTS: The 12-month prevalence of acne was 3.7% in the general population and 3.9% among AD patients. The incidence rate of acne was highest among 12- to 18-year-old AD patients, and overall slightly higher in women with AD compared with males. The overall risk in patients with AD was similar with that of the general population (HR 0.96; 95% CI 0.88-1.06), whereas the risk of being treated for severe acne was reduced in AD patients (HR 0.59; 95% CI 0.47-0.73) and mainly among adolescents and young adults. The HR of acne increased with age reaching 1.41 (95% CI 1.07-1.87) for ages 30-39 years, and 2.07 (95% CI 1.42-3.03) for patients ≥40 years compared with controls.CONCLUSIONS: The risk and severity of acne in AD patients change with age and sex, which may be used for the risk assessment of acne following treatment with Janus kinase 1 inhibitors.
AB - BACKGROUND: Use of Janus kinase 1 inhibitors in moderate-to-severe atopic dermatitis (AD) is associated with incident acne in adolescent and adults that is mostly mild, transient and treatable. There is a need for more knowledge about the risk and severity of acne in patients with AD.OBJECTIVES: To examine the prevalence, incidence and risk of acne in adolescents and adults with AD using nationwide prescription data.METHODS: A matched cohort study of 6600 adults with AD and 66 000 controls was conducted using routinely and prospectively collected nationwide administrative data. Adjusted hazard ratios (HR) are reported with 95% confidence intervals (CIs).RESULTS: The 12-month prevalence of acne was 3.7% in the general population and 3.9% among AD patients. The incidence rate of acne was highest among 12- to 18-year-old AD patients, and overall slightly higher in women with AD compared with males. The overall risk in patients with AD was similar with that of the general population (HR 0.96; 95% CI 0.88-1.06), whereas the risk of being treated for severe acne was reduced in AD patients (HR 0.59; 95% CI 0.47-0.73) and mainly among adolescents and young adults. The HR of acne increased with age reaching 1.41 (95% CI 1.07-1.87) for ages 30-39 years, and 2.07 (95% CI 1.42-3.03) for patients ≥40 years compared with controls.CONCLUSIONS: The risk and severity of acne in AD patients change with age and sex, which may be used for the risk assessment of acne following treatment with Janus kinase 1 inhibitors.
KW - Acne Vulgaris/complications
KW - Adolescent
KW - Adult
KW - Child
KW - Cohort Studies
KW - Dermatitis, Atopic/complications
KW - Female
KW - Humans
KW - Incidence
KW - Janus Kinase 1
KW - Janus Kinase Inhibitors
KW - Male
KW - Prevalence
KW - Young Adult
U2 - 10.1111/jdv.18027
DO - 10.1111/jdv.18027
M3 - Journal article
C2 - 35220619
VL - 36
SP - 890
EP - 896
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 6
ER -
ID: 307912052